Cargando…

Real‐world outcomes of chemoradiotherapy for unresectable Stage III non‐small cell lung cancer: The SOLUTION study

There are limited real‐world data on the treatment practices, outcomes, and safety of chemoradiotherapy (CRT) alone in potential candidates for immune checkpoint inhibitors (ICI) for unresectable non‐small cell lung cancer (NSCLC). In this study, we analyzed the safety and efficacy of CRT in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horinouchi, Hidehito, Atagi, Shinji, Oizumi, Satoshi, Ohashi, Kadoaki, Kato, Tomohiro, Kozuki, Toshiyuki, Seike, Masahiro, Sone, Takashi, Sobue, Tomotaka, Tokito, Takaaki, Harada, Hideyuki, Maeda, Tadashi, Mio, Tadashi, Shirosaka, Ikue, Hattori, Kana, Shin, Eisei, Murakami, Haruyasu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520333/ https://www.ncbi.nlm.nih.gov/pubmed/32730697 http://dx.doi.org/10.1002/cam4.3306

Ejemplares similares

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study
por: Shimokawa, Mototsugu, et al.
Publicado: (2020)

Proton Beam Therapy as a Curative Treatment for a Young Case of Unresectable Tracheal Adenoid Cystic Carcinoma
por: Kinoshita, Takashi, et al.
Publicado: (2023)

Impact of neutrophil-to-lymphocyte ratio throughout the course of chemoradiotherapy on overall survival and distant failure in unresectable stage III non-small cell lung cancer
por: Kanzaki, Hiromitsu, et al.
Publicado: (2021)

Pembrolizumab plus pemetrexed‐platinum for metastatic nonsquamous non–small‐cell lung cancer: KEYNOTE‐189 Japan Study
por: Horinouchi, Hidehito, et al.
Publicado: (2021)

Acute onset of ulcerative colitis during chemoradiotherapy for anaplastic lymphoma kinase‐positive lung adenocarcinoma
por: Fujita, Kohei, et al.
Publicado: (2017)

Assessment of chemotherapy regimens on radiation pneumonitis in patients with unresectable stage III non‐small‐cell lung cancer after definitive chemoradiotherapy
por: Sakaguchi, Tadashi, et al.
Publicado: (2021)

A randomized study to compare sequential chemoradiotherapy with concurrent chemoradiotherapy for unresectable locally advanced esophageal cancer
por: Gupta, Arunima, et al.
Publicado: (2014)

Unresectable Extraskeletal Myxoid Chondrosarcoma of the Neck: Early Tumor Response to Chemoradiotherapy
por: Zaki, Mark, et al.
Publicado: (2015)

A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages
por: Watanabe, Hiromi, et al.
Publicado: (2019)

Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective(§)
por: Horinouchi, Hidehito
Publicado: (2016)

To combine or not to combine: anti-vascular endothelial growth factor therapies in EGFR mutation positive non-small cell lung cancer
por: Horinouchi, Hidehito
Publicado: (2020)

Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small‐cell lung cancer in KEYNOTE‐407
por: Sugawara, Shunichi, et al.
Publicado: (2023)

Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma
por: Imai, Reiko, et al.
Publicado: (2018)

Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma
por: Kim, Young-Il, et al.
Publicado: (2013)

Unresectable esophageal cancer treated with multiple chemotherapies in combination with chemoradiotherapy: A case report
por: Yura, Masahiro, et al.
Publicado: (2021)

The Impact of Weight Loss during Chemoradiotherapy for Unresectable Esophageal Cancer: Real-World Results
por: Huang, Tzu-Ting, et al.
Publicado: (2022)

Case of hereditary kidney disease presenting thin basement membrane with a single heterozygous variant of Intersectin 2
por: Kondo, Madoka, et al.
Publicado: (2023)

Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer
por: Qiu, Bo, et al.
Publicado: (2016)

Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
por: Ochi, Masanori, et al.
Publicado: (2020)

Neoadjuvant chemoradiotherapy in patients with unresectable locally advanced sigmoid colon cancer: clinical feasibility and outcome
por: Niu, Shao-Qing, et al.
Publicado: (2021)

IDO1 Activity Predicts Lung Toxicity in Patients with Unresectable Stage III NSCLC and Chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2023)

Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis
por: Wang, Zi-Meng, et al.
Publicado: (2023)

Role of neoadjuvant chemoradiotherapy in liver transplantation for unresectable perihilar cholangiocarcinoma: multicentre, retrospective cohort study
por: Hoogwater, Frederik J H, et al.
Publicado: (2023)

Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study
por: Sakai, Hiroshi, et al.
Publicado: (2021)

Simultaneous regression of non‐small cell lung cancer and orbital extranodal marginal zone lymphoma with chemoradiotherapy for lung cancer
por: Oi, Issei, et al.
Publicado: (2023)

Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review
por: Makimoto, Go, et al.
Publicado: (2019)

Association between working hours and cancer risk in Japan: The Japan public health center‐based prospective study
por: Hattori, Kana, et al.
Publicado: (2022)

A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement
por: Harada, Daijiro, et al.
Publicado: (2019)

Potential risk of residual cancer cells in the surgical treatment of initially unresectable pancreatic carcinoma after chemoradiotherapy
por: Takano, Hironobu, et al.
Publicado: (2015)

Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy
por: Wu, Linfang, et al.
Publicado: (2022)

Successful treatment with nivolumab in a patient with unresectable oral squamous cell carcinoma following ineffective chemoradiotherapy
por: Sekido, Katsuhisa, et al.
Publicado: (2023)

Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jianing, et al.
Publicado: (2021)

Message From the New Editor-in-Chief
por: Sobue, Tomotaka
Publicado: (2013)

From the Editor-in-Chief
por: Sobue, Tomotaka
Publicado: (2010)

A message from the New Editor-in-Chief
por: Sobue, Tomotaka
Publicado: (2008)

Evaluation of Equalization of Cancer Medical Services in Japan Using Public Database in Japan
por: Sobue, Tomotaka
Publicado: (2018)

Combined chemoradiotherapy and programmed cell death‐ligand 1 blockade leads to changes in the circulating T‐cell receptor repertoire of patients with non‐small‐cell lung cancer
por: Someya, Masanori, et al.
Publicado: (2022)

Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis
por: Chang, Xiu-Jun, et al.
Publicado: (2016)

Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer
por: Chitapanarux, I, et al.
Publicado: (2010)

Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study
por: Choi, Younak, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qa6upknb3ne4on3ni1o9vms8qj